To discern whether the characteristics and outcome of invasive aspergillosis in liver transplant recipients have evolved during the past decade, 26 patients who underwent transplantation during 1990-1995 (known as "the earlier cohort") were compared with 20 patients who underwent transplantation during 1998-2001 (known as "the later cohort"). Twenty-three percent of the Aspergillus infections in the earlier cohort occurred у90 days after transplantation, compared with 55% of such infections in the later cohort ( ). The earlier cohort P p .026 was significantly more likely to have disseminated infection ( ) and central nervous system (CNS) in-P p .034 volvement ( ) than was the later cohort. The mortality rate was significantly higher for the earlier cohort P p .0004 (92%) than for the later cohort (60%;
To discern whether the characteristics and outcome of invasive aspergillosis in liver transplant recipients have evolved during the past decade, 26 patients who underwent transplantation during 1990-1995 (known as "the earlier cohort") were compared with 20 patients who underwent transplantation during 1998-2001 (known as "the later cohort"). Twenty-three percent of the Aspergillus infections in the earlier cohort occurred у90 days after transplantation, compared with 55% of such infections in the later cohort (
). The earlier cohort P p .026 was significantly more likely to have disseminated infection ( ) and central nervous system (CNS) in-P p .034 volvement ( ) than was the later cohort. The mortality rate was significantly higher for the earlier cohort P p .0004 (92%) than for the later cohort (60%;
). Only disseminated infection (not the year of transplantation) P p .012 approached statistical significance as an independent predictor of outcome. In the current era, invasive aspergillosis occurs later in the posttransplantation period, is less likely to be associated with CNS infection, and is associated with a lower mortality rate, compared with invasive aspergillosis in the early 1990s.
Invasive aspergillosis has long been recognized as one of the most significant opportunistic fungal infections in liver transplant recipients [1] [2] [3] [4] . The frequency of invasive aspergillosis among liver transplant recipients ranges from 1% to 6% [2] . However, the mortality rate for these patients exceeds 90% [1, 5] ; an estimated 16 .9% of all deaths that have occurred among liver transplant recipients have been due to Aspergillus infections [2] .
Aspergillus infections in liver transplant recipients are notable for their early occurrence. Most infections occur within the first month after transplantation; they rarely occur у90 days after transplantation [5, 6] . Virtually all liver transplant recipients with invasive aspergillosis have evidence of significant hepatic and/or renal dysfunction [7, 8] . Renal failure and, in particular, the requirement for dialysis have been shown to portend a 15-25-fold-greater risk for invasive fungal infections, including aspergillosis, among liver transplant recipients [7, 8] . Approximately one-fourth of the cases of invasive aspergillosis have occurred after retransplantation [5] . Recipients of a retransplantation have a risk for invasive aspergillosis that is 30-fold higher than that of other patients [7] . In earlier studies, cytomegaloDownloaded from https://academic.oup.com/cid/article-abstract/36/1/46/283526 by guest on 22 January 2019 virus (CMV) infection and treatment with OKT3 monoclonal antibodies were significant risk factors for the development of invasive aspergillosis in liver transplant recipients [1] . Effective antiviral prophylactic strategies have led to a decrease in the rates of CMV infection among liver transplant recipients, and the use of OKT3 has declined substantially in recent years.
Emerging data from other groups of immunocompromised hosts suggest that the epidemiology and outcome of invasive mold infections, including invasive aspergillosis, have changed. Among hematopoietic stem cell transplant recipients, it has been noted that (1) Aspergillus infections occur later in the posttransplantation period, (2) a greater proportion of these infections are due to Aspergillus species other than Aspergillus fumigatus, and (3) the risk factors predisposing to aspergillosis appear to be evolving [9, 10] . However, the high mortality rate associated with invasive aspergillosis in these patients remains persistent. To assess whether the demographic characteristics of the patients, the timing of the onset of infection, the risk factors for and spectrum of infection, and the outcome for patients with invasive aspergillosis after liver transplantation have evolved during the past decade, we compared liver transplant recipients with invasive aspergillosis in the current era with those who underwent transplantation in the early 1990s.
METHODS
The study population comprised 46 liver transplant recipients with invasive aspergillosis. Data were from multiple centers and were prospectively collected. A cohort of 26 liver transplant recipients who underwent transplantation during 1990-1995 (hereafter known as "the earlier cohort") was compared with a cohort of 20 patients who underwent transplantation during 1998-2001 (hereafter known as "the later cohort"). The clinical care provided to the patients and the immunosuppressive regimens administered were as per the standard of care at that institution. Invasive aspergillosis was diagnosed on the basis of both histopathological examination of tissue specimens that demonstrated acute-angle, septate hyphae and a positive result of culture for Aspergillus species [1, 2, 8] . Thus, all patients had proven invasive aspergillosis as per the European Organization for Research and Treatment for Cancer/Mycoses Study Group criteria [11] . Involvement of у2 noncontiguous organs was defined as disseminated infection. Invasive aspergillosis was considered to be "early-onset infection" if it occurred !90 days after transplantation or "late-onset infection" if it occurred у90 days after transplantation [5] . The epidemiologic characteristics and outcome of Aspergillus infections in the earlier cohort have been described elsewhere [5] .
Patient demographics (e.g., age, sex. etc.) and laboratory data were entered into PROPHET statistical software (BBN Systems 
RESULTS

Characteristics of the Entire Cohort
A total of 2449 patients in the earlier cohort and 1685 patients in the later cohort underwent transplantation at the participating study sites. Thus, the incidence of invasive aspergillosis (which was 1.06% in the earlier cohort and 1.18% in the later cohort) did not differ significantly between the 2 cohorts. The mean age of the patients with invasive aspergillosis was 47.2 years (range, 16-67 years). Fifty-nine percent of the patients were male. Twelve (26%) of the 46 patients with invasive aspergillosis had undergone retransplantation, and 33 (72%) of 46 were in the intensive care unit at the time of diagnosis. The median levels of total bilirubin and serum creatinine were 13 mg/dL (range, 0.1-63.8 mg/dL) and 2.3 mg/dL (range, 0.6-10.3 mg/dL), respectively. Fifty-five percent of the patients had serum creatinine levels of 12.0 mg/dL, and 50% required dialysis. Only 2% (1 of 46) of the patients had a WBC count of !1000 cells/mm 3 . Twenty-two (48%) of 46 patients had disseminated invasive aspergillosis, 20 (43%) had pulmonary infection only, and 4 (9%) had extrapulmonary infection only. The sites of involvement are shown in table 1. CNS infection was present in 12 patients (26%). The Aspergillus species involved were A. fumigatus in 78% (36 patients), A. flavus in 15% (7 patients), and A. terreus in 2% (1 patient). One patient had A. fumigatus and A. flavus infection, and another had A. fumigatus and Aspergillus niger infection.
Comparison of the 2 Cohorts of Liver Transplant Recipients
Clinical characteristics of the patients. Of the earlier cohort of 26 patients, 12 patients (46%) had received tacrolimus, and 14 patients (54%) had received cyclosporine as primary immunosuppressive agents. The use of tacrolimus had increased in the later cohort of 20 patients; 14 patients (70%) had received tacrolimus, and 6 patients (30%) had received cyclosporine (table 2) . However, the difference in the primary immunosuppressive agent received was not statistically significant between the 2 cohorts. The earlier cohort was more critically ill, as was reflected by the United Network of Organ Sharing (UNOS) status of the 2 cohorts, and, unlike the later cohort, it included ) than did the later cohort (table 2) . Eighty-one per-P p .0032 cent of patients in the earlier cohort (21 of 26 patients) were in the intensive care unit at the time of diagnosis, compared with 60% of those in the later cohort (12 of 20 patients) (
). The earlier cohort had a lower total WBC count at P p .12 the onset of infection ( ); however, the proportion of P p .05 patients with neutropenia did not differ between groups (table 2) .
Timing of onset and characteristics of Aspergillus infections. Aspergillus infections were significantly less likely to occur у90 days after transplantation in the earlier cohort than in the later cohort; 6 (23%) of 26 Aspergillus infections in the earlier cohort versus 11 (55%) of 20 of those in the later cohort were late-onset infections ( ) ( ). Eighty-P p .0004 one percent of the infections in the earlier cohort were due to A. fumigatus, as were 75% of those in the later cohort (P 1 ). A single case of A. terreus infection was observed in the .20 later cohort.
Outcome
The overall mortality rate in the study population was 78% (36 of 46 patients died). However, the mortality rate was significantly higher in the earlier cohort (92% ); 1 patient in the later cohort received a diagnosis only P p .02 at autopsy, and another patient in the earlier cohort received itraconazole as therapy for Aspergillus infection. The dosage of lipid formulations of amphotericin B administered did not differ for the 2 cohorts (table 3). The median time from the onset of infection to the initiation of therapy directed against Aspergillus infection was 2 days for both cohorts.
In the entire study population, the mortality rate was lower among patients who had received a lipid formulation of amphotericin B (65% [15 of 23 patients]) than among those who had received amphotericin B deoxycholate as therapy for invasive aspergillosis (90% [19 of 21 patients];
). How-P p .03 ever, within the 2 cohorts of patients, the mortality rate did not differ for patients who had received lipid formulations of amphotericin B and those who had received amphotericin B deoxycholate (table 3) . By Kaplan-Meier analyses, the probability of survival !90 days after infection was 43% in the group ], and the later cohort [OR, 0.25; P p .14 95% CI, 0.04-1.6; ]), which suggests that these variables P p .14 were interrelated. When the data were analyzed along with the year of transplantation in the model, only disseminated infection (OR, 5.76; 95% CI, 0.9-35.5;
) approached sta-P p .058 tistical significance as an independent predictor of mortality, whereas the use of lipid formulations of amphotericin B (OR, 0.25; 95% CI, 0.03-1.8;
) and the year of transplantation P p .16 (OR, 0.89; 95% CI, 0.7-1.1;
) were not significant. P p .32
Early-versus Late-Onset Infection
Twenty-nine (63%) of 46 cases of invasive aspergillosis in the entire cohort occurred !90 days after transplantation (table 4) . Patients with early-onset invasive aspergillosis were more likely to be in the intensive care unit at the time of diagnosis (P p ) and to have CNS involvement ( ). The 2 sub-.004 P p .03 groups, however, did not differ with regard to other characteristics shown in table 4.
DISCUSSION
Our study documents a number of significant trends in the characteristics of and outcomes for liver transplant recipients with invasive aspergillosis. We show that Aspergillus infections in liver transplant recipients are occurring later in the posttransplantation period. Indeed, 55% of these infections now occur after the first 3 months following transplantation. A trend toward later onset of Aspergillus infections has also been noted among patients undergoing hematopoietic stem cell transplantation, in whom longer survival and delayed occurrence of graft-versus-host disease are largely proposed to account for this phenomenon [9, 10] .
Precise reasons for the later occurrence of invasive aspergillosis in liver transplant recipients are unclear. In recent years, technical surgical advances and better management have led to a lower frequency of organ system failures and have improved outcome in the early postoperative period. Thus, patients at risk in the early 1990s, who may not have survived, now likely constitute a growing group who still develop Aspergillus infections, albeit in the later posttransplantation period. The incidence of CMV infection preceding invasive aspergillosis did not differ in the 2 cohorts. However, CMV infection in organ transplant recipients in the current era of ganciclovir prophylaxis is occurring later [12, 13] . In this context, a risk factor for invasive aspergillosis may merely have been delayed, thus accounting for the later occurrence of opportunistic infections, such as invasive aspergillosis. In addition, hepatitis C virus as an underlying liver disease has become an increasingly common indication for liver transplantation in recent years [14] . Indeed, the frequency of hepatitis C virus as an underlying liver disease in patients in the later cohort was 3-fold higher than was that in the earlier cohort. Significant allograft dysfunction is a known risk for aspergillosis, and, because hepatic dysfunction in patients undergoing liver transplantation for hepatitis C virus often occurs later in the posttransplantation period, another risk factor for invasive aspergillosis may now be occurring later.
Regardless, the delayed occurrence of invasive aspergillosis among liver transplant recipients has relevant implications. Although the efficacy of prophylactic approaches against Aspergillus infection has not been incontrovertibly documented, antifungal prophylaxis is frequently limited to the early posttransplantation period [15] [16] [17] . In addition, surveillance monitoring for Aspergillus galactomannan antigen in the early transplantation period has been proposed as a promising tool for the early diagnosis of invasive aspergillosis in transplant recipients. Our data suggest that such strategies may potentially prevent fewer than half of the cases of invasive aspergillosis, because most infections occurred after 3 months following transplantation. Thus, prophylactic strategies for invasive aspergillosis may have to be guided on the basis of the presence or development of risk factors, regardless of the time elapsed relative to transplantation.
Although the frequency of retransplantation and the requirement of dialysis remained unchanged in the 2 cohorts, the more recent cohort of patients developed invasive aspergillosis despite having better allograft function and renal function than were found in the earlier cohort. The later cohort, however, had a trend toward a higher frequency of episodes of transplant rejection preceding invasive aspergillosis. An intriguing finding in our study was a striking decrease in the incidence of CNS involvement in the later cohort. Whether the increasing use of imaging studies in recent years for the detection of difficultto-define abnormalities on chest radiographs and earlier diagnosis during the course of infection account for this observation is speculative. A functioning hepatic allograft is proposed to be a major line of defense against the dissemination of Aspergillus organisms; injury to the hepatic reticuloendothelial phagocytes is thought to greatly increase susceptibility to aspergillosis [2] . It is plausible that a lesser severity of hepatic dysfunction in the later cohort accounted for a lower risk of disseminated infection and CNS involvement.
The mortality rate among liver transplant recipients with invasive aspergillosis has been shown to exceed 90% [1, 5] . The mortality rate among liver transplant recipients in the later cohort of patients in our study was 60%, and it had decreased significantly, compared with the mortality rate in the earlier cohort (92%;
). In the total study population, the mor-P p .012 tality rate was lower among patients who had received a lipid formulation of amphotericin B. However, when stratified by cohort, there was no significant difference in the mortality rate among patients who had received a lipid formulation of amphotericin B, compared with those who had received amphotericin B deoxycholate (table 3) . These data suggest that the decrease in the mortality rate was not attributable to the higher frequency of use of lipid formulations of amphotericin B in recent years. An overall lesser severity of illness in the later cohort and a lower incidence of disseminated and CNS involvement may have been greater contributors to the observed decline in deaths among liver transplant recipients in the recent years.
Although our data were from multiple centers, a limitation of the present study is that only 2 of the participating sites were common in both study periods. However, within each cohort, the characteristics of the patients and the variables assessed (UNOS status, rate of retransplantation, CMV infection, total bilirubin, requirement of dialysis, and mortality rate) did not differ significantly between study sites. Thus, our findings likely reflect wide, and not merely institutional, trends regarding invasive aspergillosis.
In conclusion, the risk profile and the epidemiology of invasive aspergillosis in liver transplant recipients has changed. Invasive aspergillosis seen in the current era occurs later, is less likely to be associated with CNS infection, and is associated with a lower mortality rate, compared with invasive aspergillosis seen in the early 1990s. Implications of these trends in directing antifungal prophylaxis have been discussed earlier in the present report. Our findings, however, are clinically relevant for another reason. Performance of prospective trials for the treatment of invasive aspergillosis has proven logistically difficult and challenging [18] . Therefore, comparisons to discern the efficacy of therapeutic regimens have often been made with historical controls [5, 19, 20] . Such trials have invariably documented the superiority of newer agents over those used to treat historical controls [5, 19, 20] . On the basis of our findings, it is rational to speculate that the differences in outcome may merely have been the result of the changes in the risk profile and epidemiology of the infection and of the fact that the patients were studied during different time periods, rather than the result of the direct impact of the therapeutic regimen. Finally, a number of novel antifungal agents are on the horizon, and combination therapies are considered potentially promising therapeutic modalities for invasive aspergillosis. We propose that the goal of therapy should be to improve upon the 60% mortality rate observed among liver transplant recipients with the current standard (i.e., lipid formulations of amphotericin B) and not the higher rates (exceeding 90%) observed in the early 1990s.
